Table 4.
Correlation of LV-ECV in PAF patients.
| Parameters | LV-ECV | |
|---|---|---|
| r | P value | |
| Age | 0.18 | 0.06 |
| NT-proBNP* | 0.33 | 0.001 |
| LVEF | − 0.019 | 0.85 |
| LVMI | − 0.08 | 0.42 |
| E/e′* | 0.30 | 0.002 |
| LAVImax* | 0.31 | 0.001 |
| LAVIpre-ac* | 0.32 | 0.001 |
| LAVImin* | 0.30 | 0.002 |
| PAF duration | − 0.09 | 0.40 |
| Number of antiarrhythmic drugs* | 0.20 | 0.04 |
| Reservoir function | ||
| Total LAEF (%)* | − 0.19 | 0.05 |
| Total LA strain (%)* | − 0.21 | 0.03 |
| SRt (s−1) | − 0.17 | 0.08 |
| Conduit function | ||
| Passive LAEF (%) | − 0.18 | 0.07 |
| Passive LA strain (%)* | − 0.25 | 0.009 |
| SRp (s−1)* | 0.28 | 0.004 |
| Booster pump function | ||
| Active LAEF (%) | − 0.14 | 0.15 |
| Active LA strain (%) | − 0.09 | 0.38 |
| SRa (s−1) | 0.14 | 0.16 |
ECV extracellular volume fraction, LAEF left atrial empty fraction, LAVI left atrial volume index, LV left ventricular, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, NT-proBNP N terminal pro B type natriuretic peptide, PAF paroxysmal atrial fibrillation, SR strain rate. *P < 0.05.